DOR BioPharma, Inc. Receives Orphan Drug Designation for Oral BDP for the Treatment of Pediatric Crohn's Disease
EWING, NJ--(Marketwire - January 03, 2008) - DOR BioPharma, Inc., (OTCBB: DORB) ("DOR" or the "Company") announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Oral BDP (beclomethasone dipropionate) for the treatment of pediatric Crohn's disease.